PDCD1 and non-small cell lung carcinoma: The findings of this study partly explained why single anti-CTLA-4 inhibitor treatment is not as effective as anti-PD-1/PD-L1 ICIs for advanced NSCLC clinically, either in objective response rate or prolonging survival.